Efficacy of Immune System Challenges with Tiny Enemy COVID-19
Article Sidebar
Main Article Content
Abstract
The objective of this review article was to discuss the interaction between virus effectiveness and host immune system challenges on the innate and adaptive on how the immune system able to defend against COVID-19 viral infections. Genetically, the COVID-19 is a virus that has genetic material coated by lipid with a crown of protein. The virus that causes COVID-19 is called severe acute respiratory syndrome coronavirus two (SARS-COV-2) and was first detected in humans last December 2019. Primarily, the COVID-19 virus spreads with droplets of saliva or nose discharge when an infected person sneezes or coughs. Most people with a healthy immune system those infected with the COVID-19 virus showed mild to moderate respiratory illness and recovered without needing special treatment. The aged people those had medical problems such as cardiovascular disease, diabetes, chronic respiratory disease, and cancer are most likely to develop serious illness. In-conclusion: Little is known about viral clearance, but regulation innate immune response associated with development of adaptive immunity neutralizing antibodies, memory T and B lymphocytes in convalescent patients raises hope for active immunization.
Downloads
Article Details
How to Cite
References
Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424-432.
Bouvier NM, Lowen AC. Animal Models for Influenza Virus Pathogenesis and Transmission. Viruses. 2010; 2(8):1530-1563.
Rudragouda C, Jincun Z, Stanley P. T cell-mediated immune response to respiratory coronaviruses Immunol Res. 2014; 59(1):
–128.
Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol. 2004; 78(11):5535-45.
Saha B, Jyothi Prasanna S, Chandrasekar B, Nandi D. Gene modulation and immunoregulatory roles of interferon gamma. Cytokine. 2010;50(1):1-14.
Román E, Miller E, Harmsen A, Wiley J, Von Andrian UH, Huston G. et al. CD4 effector T cell subsets in the response to influenza: heterogeneity, migration, and function. J Exp Med. 2002;196(7):957-68.
Judith A, Owe AO, Punt J, Stranford SHA, Jones PP. Innate immunity. In Kuby immunology,7th ed., W. H. Freeman and Company, U.S.A. 2013; Chap57, Immunology: p.152-160.
Xu H. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J. Oral. Sci. 2020; 12 (8).
Liao YC, Liang WG, Chen FW, Hsu JH, Yang JJ, Chang MS. IL-19 induces production of IL-6 and TNF-α and results in cell apoptosis through TNF-α. The Journal of Immunology. 2002; 15;169(8): 4288-97.
Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor cell–derived lactic acid on human T cells. Blood. 2007: May 1; 109(9): 3812-9.
Kritas SK, Ronconi G,Caraffa A, Gallenga CE, Ross R, Conti P. Mast cells contribute to coronavirus-induced inflammation: new anti-
inflammatory strategy. Biol Regul Homeost Agents. 2020; 34(1). doi: 10.23812/20-Editorial-Kritas.
Can an Old Vaccine Stop the New Coronavirus? By Roni Caryn Rabin https://www.nytimes.com/2020/04/03/health/coronavirus-bcg-vaccine.html.
WHO. Bacille Calmette-Guérin (BCG) vaccination and COVID-19 (2020).
Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine (BCG-CORONA). https://clinicaltrials.gov/ct2/show/NCT04328441,2020.
Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80–90.
WHO. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. 2020.
Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38(1):10–18.
Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) (2009). Virus infection. Clin Infect Dis. 2011;52(4):447–456.
Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1): 69–71.
Kim JY, Ko JH, Kim Y, Kim YJ, Kim JM, Chung YS, et al. Viral load kinetics of SARS-COV-2 infection in first two patients in Korea. J Korean Med Sci. 2020;35(7):p.86.
Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human